PVLA
Palvella Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 82 | +9 | 6.93M | $1.05B | +11 | −2 |
| Q1 2026 | 76 | +14 | 6.06M | $750.08M | +17 | −3 |
| Q4 2025 | 62 | +2 | 4.35M | $454.99M | +2 | — |
| Q3 2025 | 14 | +3 | 2.25M | $140.88M | +4 | −1 |
| Q2 2025 | 8 | 0 | 1.30M | $29.21M | — | — |
| Q1 2025 | 5 | +2 | 421.70K | $11.80M | +3 | −1 |
| Q4 2024 | 3 | +3 | 46.05K | $552,635 | +3 | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 269.84K | New | $7.55M | 0.0% | New | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 94.20K | +560.1% | $2.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 94.20K | +560.1% | $2.64M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 30.34K | New | $849,356 | 0.0% | New | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 30.34K | New | $849,356 | 0.0% | New | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 15.26K | -28.6% | $427,071 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | State Street Global Advisors ✦ (passive) | 12.06K | New | $337,615 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $7.55M | 0.0% |
| Marshall Wace | $849,356 | 0.0% |
| Marshall Wace | $849,356 | 0.0% |
| State Street Global Advisors | $337,615 | 0.0% |
Exited
| Citadel Advisors | $124,896 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 181 holders, 13.20M shares, $1.59B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.50K sh · $227,085
Officer · 2.00K sh · $303,292
Officer · 400 sh · $61,199
Officer · 102 sh · $15,870
Officer · 302 sh · $47,345
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology